Hope for pancreatic cancer prevention: old drug, new trial

NCT ID NCT04207944

Ongoing Prevention Sponsor: Duke University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the anti-inflammatory drug sulindac can prevent high-risk pancreatic cysts (IPMNs) from progressing to pancreatic cancer. About 100 adults with these cysts will receive either sulindac or a placebo for up to 3 years, alongside standard monitoring. The goal is to see if the drug reduces cyst growth, new cysts, or cancer development.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM OF THE PANCREAS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Pancreatic Intraductal Neoplasms pancreatic intraductal papillary-mucinous neoplasm malignant pancreatic neoplasm prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IPMN IPMN, PANCREATIC

Contacts and locations

Locations

Duke University Medical Center

Durham, North Carolina, 27710, United States
Johns Hopkins University

Baltimore, Maryland, 21287, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering

New York, New York, 10021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.